Updates in Metastatic Prostate Cancer: Guidance for the Multidisciplinary Team and VA Systems

Join us for this live 1-hour, CME/CE/CPE-certified workshop series to learn how healthcare professionals in the community and Veterans Affairs can effectively incorporate newly approved and emerging treatment regimens into the care of patients with metastatic prostate cancer.

To Register: On the Event Dates page, click a date/time, then click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the webinar.

Agenda

  • Welcome, Introduction, and Baseline Assessment
  • Individualizing Treatment in Prostate Cancer
  • Integrating Patient Preferences
  • Clinical Pearls/Applications: Prostate Cancer Care and Evolution
  • Closing Remarks and Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Chair
Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology
Director, Prostate and GU Medical Oncology
Co-Director, Cancer Signaling Network Program 
Yale Cancer Center
New Haven, Connecticut

Program Chair
David VanderWeele, MD, PhD

Associate Professor
Hematology/Oncology
Northwestern University
Attending Physician
Hematology/Oncology
Northwestern Medicine
Chicago, Illinois

Goal Statement
The goal of this activity is to improve learners’ knowledge, competence, and performance in applying practice-changing clinical data and expert recommendations to integrate the use of currently available therapies for their patients with metastatic prostate cancer.

Target Audience
This program is intended for oncologists, nurses, pharmacists, and other healthcare professionals on the multidisciplinary team caring for patients with prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate novel therapeutically actionable molecular targets that hold promise as predictive or prognostic biomarkers for patients with metastatic prostate cancer
  • Plan optimal, individualized sequential therapeutic strategies for metastatic prostate cancer, considering all available agents, clinical data including novel imaging techniques, and expert recommendations
  • Counsel patients with metastatic prostate cancer on available therapies, taking into consideration patient preferences regarding differences in administration and safety profiles, as well as comorbidities and patient goals
  • Identify patients with metastatic prostate cancer who may be eligible for enrollment on ongoing clinical studies investigating novel regimens

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-022-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.